Behavioral, cognitive and psychophysiological effects of cannabinoids: Relevance to psychosis and schizophrenia;Efeitos comportamentais, cognitivos e psicofisiológicos de canabinoids: Relevância para a psicose e esquizofrenia

Revista Brasileira de Psiquiatria

Volumn 32, Issue SUPPL. 1, 2010, Pages

  Sewell, R Andrew ^a,b,c   Skosnik, Patrick D ^a,b,c   Garcia Sosa, Icelini ^a,b,c   Ranganathan, Mohini ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptation; Cannabinoids; Cannabis; Cognition; Physiological drug effects; Schizophrenia

Indexed keywords

CANNABINOID;

CANNABIS ADDICTION; COGNITIVE DEFECT; DISEASE COURSE; HUMAN; METABOLISM; PSYCHOSIS; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

CANNABINOIDS; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 79851503776     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (226)

1. Warnock J. Insanity from hasheesh. J Mental Science. 1903;49:96-110.
2. Moreau J. Hashish and Mental Illness. New York: Raven; 1973.
3. Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005;78(5):539-48.
4. Marshall C. The active principle of Indian help; a preliminary communication. Lancet. 1897;1:235-8.
5. D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol. 2007;78:289-326.
6. Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry. 1974;30(1):24-7.
7. Smith DE. Acute and chronic toxicity of marijuana. J Psychedelic Drugs. 1968;2:37-47.
8. Spencer DJ. Cannabis-induced psychosis. Int J Addict. 1971;6(2):323-6.
9. Grossman W. Adverse reactions associated with Cannabis products in India. Ann Intern Med. 1969;70(3):529-33.
10. Talbott JA, Teague JW. Marihuana psychosis. Acute toxic psychosis associated with the use of Cannabis derivatives. JAMA. 1969;210(2):299-302.
11. Thacore VR. Bhang psychosis. Br J Psychiatry. 1973;123(573):225-9.
12. Keeler MH, Moore E. Paranoid reactions while using marijuana. Dis Nerv System. 1974;35(11):535-6.
13. Brook M. Psychosis after cannabis abuse. BMJ. 1984;288:1381.
14. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003;22(4):453-60.
15. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction. 1998;93(6):837-46.
16. Citron ML, Herman TS, Vreeland F, Krasnow SH, Fossieck BE Jr, Harwood S, Franklin R, Cohen MH. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep. 1985;69(1):109-12.
17. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. Journal of clinical pharmacology. J Clin Pharmacol. 1981;21(8-9 Suppl):43S-50S.
18. Diasio RB, Ettinger DS, Satterwhite BE. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J Clin Pharmacol. 1981;21(8-9 Suppl):81S-5S.
19. Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 1984;13(2):123-5.
20. Heim ME, Romer W, Queisser W. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 1981;21(8-9 Suppl):86S-9S.
21. Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21(8-9 Suppl):320S-6S.
22. Kenny JB, Wilkinson PM. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Clin Oncology. 1982;8(4): 335-9.
23. Laszlo J, Lucas VS Jr, Hanson DC, Cronin CM, Sallan SE. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J Clin Pharmacol. 1981;21(8-9 Suppl):51S-6S.
24. Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J Clin Pharmacol. 1984;24(4):155-9.
25. Stuart-Harris RC, Mooney CA, Smith IE. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. Clin Oncology. 1983;9(2):143-6.
26. Roxane US. Marinol product monograph. Montvale, NJ: Medical Economics Company;1998.
27. Volkow N, Fowler J, Wolf A, Gillespi H. Metabolic studies of drugs of abuse. Bethesda, MD: National Institute of Drug Abuse; 1991. Report No.:105.
28. Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl). 1999;142(3):230-5.
29. Wesnes K, Annas P, Edgar C, Deeprose C, Karlsten R, Philipp A, Kalliomäki J, Segerdahl M. Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol. In press 2009.
30. Stambaugh JE Jr, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J Clin Pharmacol. 1984;24(11-12):480-5.
31. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapyinduced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl). 2008;17(5):431-43.
32. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323(7303):16-21.
33. Mayor'S Committee on Marijuana. The LaGuardia Committee Report: The Marihuana Problem in the City of New York. New York: The New York Academy of Medicine; 1944.
34. Ames F. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J Mental Science. 1958;104(437):972-99.
35. Isbell H, Gorodetzsky CW, Jasinski D, Claussen U, von Spulak F, Korte F. Effects of (--)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia. 1967;11(2):184-8.
36. Isbell H, Jasinski DR. A comparison of LSD-25 with (-)-delta-9-transtetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia. 1969;14(2):115-23.
37. Renault PF, Schuster CR, Freedman DX, Sikic B, de Mello DN. Repeat administration of marihuana smoke to humans. Arch Gen Psychiatry. 1974;31(1):95-102.
38. Melges FT, Tinklenberg JR, Hollister LE, Gillespie HK. Marihuana and temporal disintegration. Science. 1970;168(935):1118-20.
39. Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986;38(1):1-20.
40. Jones RT, Stone GC. Psychological studies of marijuana and alcohol in man. Psychopharmacologia. 1970;18(1):108-17.
41. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29(8):1558-72.
42. Morrison PD, Zois V, McKeown DA, Lee TD, Holt DW, Powell JF, Kapur S, Murray RM. The acute effects of synthetic intravenous Delta9- tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39(10):1607-16.
43. Leweke FM, Schneider U, Radwan M, Schmidt E, Emrich HM. Different effects of nabilone and cannabidiol on binocular depth inversion in Man. Pharmacol Biochem Behav. 2000;66(1):175-81.
44. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188(4):425-44.
45. Miller LL, McFarland D, Cornett TL, Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol Biochem Behav. 1977;7(2):99-103.
46. Marks DF, MacAvoy MG. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology (Berl). 1989;99(3):397-401.
47. Leweke M, Kampmann C, Radwan M, Dietrich DE, Johannes S, Emrich HM, Münte TF. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology. 1998;37(2):104-11.
48. Hooker WD, Jones RT. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology (Berl). 1987;91(1):20-4.
49. Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology. 2001;25(5):757-65.
50. Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav. 1990;37(3):561-5.
51. Lichtman AH, Varvel SA, Martin BR. Endocannabinoids in cognition and dependence. Prostaglandins Leukot Essent Fatty Acids. 2002;66(2-3): 269-85.
52. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82.
53. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12(3):426-45.
54. Turner WM, Tsuang MT. Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull. 1990;16(1):87-95.
55. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol Med. 1986;16(3):515-20.
56. Linszen D, van Amelsvoort T. Cannabis and psychosis: an update on course and biological plausible mechanisms. Curr Opin Psychiatry. 2007;20(2):116-20.
57. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet. 1987;2(8574): 1483-6.
58. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry. 1990;157:25-33.
59. Hall W, Solowij N. Adverse effects of cannabis. Lancet. 1998;352(9140): 1611-6.
60. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depende. 2003; 71(1):37-48.
61. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatrica Scand. 1992;85(2):127-30.
62. Baeza I, Graell M, Moreno D, Castro-Fornieles J, Parellada M, Gonzalez- Pinto A, Payá B, Soutullo C, de la Serna E, Arango C. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr Res. 2009;113(2-3):129-37.
63. Lindemann E, Malamud W. Experimental analysis of the psychopathological effects of intoxicating drug. Am J Psychiatry. 1934;90:853-81.
64. D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH. Delta-9- tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
65. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585-614.
66. Iversen L. Cannabis and the brain. Brain. 2003;126(Pt 6):1252-70.
67. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.
68. Johnson BA, Smith BL, Taylor P. Cannabis and schizophrenia. Lancet. 1988;1(8585):592-3.
69. Johnson BA. Psychopharmacological effects of cannabis. Br J Hospital Med. 1990;43(2):114-6, 118-20, 122.
70. Negrete JC. Cannabis and schizophrenia. Br J Addiction. 1989;84(4):349-51.
71. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3.
72. Weiser M, Knobler HY, Noy S, Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet. 2002;114(8):949-55.
73. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002;156(4):319-27.
74. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ. 2005;330(7481):11.
75. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370(9584):319-28.
76. Hickman M, Vickerman P, Macleod J, Kirkbride J, Jones PB. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction. 2007;102(4):597-606.
77. Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull. 2005;31(3):608-12.
78. Aust R, Sharp C, Goulden C. Prevalence of drug use: key findings from the 2001/2002 British Crime Survey, findings 182. London: Home Office Research, Development and Statistics Directorate; 2002.
79. Der G, Gupta S, Murray RM. Is schizophrenia disappearing? Lancet. 1990;335(8688):513-6.
80. Ajdacic-Gross V, Lauber C, Warnke I, Haker H, Murray RM, Rossler W. Changing incidence of psychotic disorders among the young in Zurich. Schizophr Res. 2007;95(1-3):9-18.
81. Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North Am. 1986;9(3):533-45.
82. Halikas J, Weller R, Morse C. Effects of regular marijuana use on sexual performance. J Osychoactive Drugs. 1982;14(1-2):59-70.
83. Kolansky H, Moore WT. Effects of marihuana on adolescents and young adults. J Psychiatr Nurs Mental Health Serv. 1971;9(6):9-16.
84. Tennant FS Jr, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry. 1972;27(1):133-6.
85. Hollister LE. Cannabis-1988. Acta Psychiatrica Scand. 1988;345:108-18.
86. Rubin V, Comitas L. Ganja in Jamaica: a medical anthropological study of chronic Marihuana use. The Hague: Mouton Publishers; 1975.
87. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909-15.
88. Pope HG Jr, Gruber AJ, Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995;38(1):25-34.
89. Pope HG Jr, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA. 1996;275(7):521-7.
90. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol Biochem Behav. 2005;81(2):319-30.
91. Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1(1):81-98.
92. Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337-43.
93. Solowij N, Michie PT. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci. 2007;32(1):30-52.
94. Gonzalez R, Carey C, Grant I. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review. J Clin Pharmacol. 2002;42(11 Suppl):48S-57S.
95. Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology (Berl). 2006;185(3):358-68.
96. Pope HG Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58(10):909-15.
97. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana- -a comparison with pre-drug performance. Neurotoxicol Teratol. 2005;27(2):231-9.
98. Solowij N. Do cognitive impairments recover following cessation of cannabis use? Life Sci. 1995;56(23-24):2119-26.
99. Loberg EM, Hugdahl K. Cannabis use and cognition in schizophrenia. Front Hum Neurosci. 2009;3:53.
100. Chan GC, Hinds TR, Impey S, Storm DR. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci. 1998;18(14):5322-32.
101. Landfield PW, Cadwallader LB, Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res. 1988;443(1-2):47-62.
102. Landfield PW. Delta-9-tetrahydrocannabinol-dependent alterations in brain structure. NIDA Res Monogr. 1987;78:143-57.
103. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res. 2000;877(2):407-10.
104. Scallet AC. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav. 1991;40(3):671-6.
105. Campbell AM, Thomson JL, Evans M, Williams MJ. Cerebral atrophy in young cannabis smokers. Lancet. 1972;1(7743):202-3.
106. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA. 1977;237(12):1229-30.
107. Hannerz J, Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Ann Neurol. 1983;13(2):207-10.
108. Kuehnle J, Mendelson JH, Davis KR, New PF. Computed tomographic examination of heavy marijuana smokers. JAMA. 1977;237(12):1231-2.
109. Tzilos GK, Cintron CB, Wood JB, Simpson NS, Young AD, Pope HG Jr, Yurgelun-Todd DA. Lack of hippocampal volume change in long-term heavy cannabis users. Am J Addict. 2005;14(1):64-72.
110. Block RI, O'Leary DS, Ehrhardt JC, Augustinack JC, Ghoneim MM, Arndt S, Hall JA. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport. 2000;11(3):491-6.
111. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis. 2000;19(1):1-22.
112. Matochik JA, Eldreth DA, Cadet JL, Bolla KI. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 2005;77(1):23-30.
113. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol Teratol. 2007;29(1):141-52.
114. Cahn W, Hulshoff Pol HE, Caspers E, van Haren NE, Schnack HG, Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res. 2004;67(2-3):305-7.
115. Wobrock T, Sittinger H, Behrendt B, D'Amelio R, Falkai P. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur Arch Psychiatry Clin Neurosci. 2009;259(1):28-36.
116. Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry. 2007;190:230-6.
117. Bangalore SS, Prasad KM, Montrose DM, Goradia DD, Diwadkar VA, Keshavan MS. Cannabis use and brain structural alterations in first episode schizophrenia--a region of interest, voxel based morphometric study. Schizophr Res. 2008;99(1-3):1-6.
118. Potvin S, Mancini-Marie A, Fahim C, Mensour B, Levesque J, Karama S, Beauregard M, Rompré PP, Stip E. Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Res. 2007;154(3):275-9.
119. Rais M, Cahn W, van Haren N, Schnack H, Caspers E, Hulshoff Pol H, Kahn R Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry. 2008;165(4):490-6.
120. Peters BD, de Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull. 2009;42(2):75-88.
121. Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, de Haan L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res. 2010;181(1):51-6.
122. Struve FA, Straumanis JJ. Electroencephalographic and evoked-potential methods in human Marijuana research: Historical review and futuretrends. Drug Develop Res. 1990;20(3):369-88.
123. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007;33(1):69-94.
124. Heinrichs RW. Meta-analysis and the science of schizophrenia: variant evidence or evidence of variants? Neurosci Biobehav Rev. 2004;28(4):379-94.
125. Thaker GK. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr Bull. 2008;34(4):760-73.
126. Boutros NN, Belger A, Campbell D, D'Souza C, Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res. 1999;88(2):119-30.
127. Braff DL, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004;174(1): 75-85.
128. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res. 2008;158(2):226-47.
129. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull. 2006;32(4):692-700.
130. de Wilde OM, Bour LJ, Dingemans PM, Koelman JH, Linszen DH. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr Res. 2007;97(1-3):137-51.
131. Bramon E, Rabe-Hesketh S, Sham P, Murray RM, Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr Res. 2004;70(2-3):315-29.
132. Cadenhead KS, Light GA, Geyer MA, Braff DL. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am J Psychiatry. 2000;157(1):55-9.
133. Grunwald T, Boutros NN, Pezer N, von Oertzen J, Fernandez G, Schaller C, Elger CE. Neuronal substrates of sensory gating within the human brain. Biol Psychiatry. 2003;53(6):511-9.
134. Luntz-Leybman V, Bickford PC, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992;587(1):130-6.
135. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex. 2007;17(1):175-91.
136. Zachariou M, Dissanayake DW, Coombes S, Owen MR, Mason R. Sensory gating and its modulation by cannabinoids: electrophysiological, computational and mathematical analysis. Cogn Neurodyn. 2008;2(2): 159-70.
137. Dissanayake DW, Zachariou M, Marsden CA, Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. Neuropharmacology. 2008;55(8):1397-404.
138. Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry. 2008;63(11):1075-83.
139. Patrick G, Straumanis JJ, Struve FA, Fitz-Gerald MJ, Leavitt J, Manno JE. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biol Psychiatry. 1999;45(10):1307-12.
140. Patrick G, Struve FA. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin Electroencephalogr. 2000;31(2):88-93.
141. Edwards CR, Skosnik PD, Steinmetz AB, O'Donnell BF, Hetrick WP. Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations. Behav Neurosci. 2009;123(4):894-904.
142. Rentzsch J, Penzhorn A, Kernbichler K, Plockl D, Gomez-Carrillo de Castro A, Gallinat J, Jockers-Scherübl MC. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp Neurol. 2007;205(1):241-9.
143. Polich J, Criado JR. Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol. 2006;60(2):172-85.
144. Kiehl KA, Laurens KR, Duty TL, Forster BB, Liddle PF. Neural sources involved in auditory target detection and novelty processing: an eventrelated fMRI study. Psychophysiology. 2001;38(1):133-42.
145. Jeon YW, Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology. 2003;40(5):684-701.
146. Bramon E, McDonald C, Croft RJ, Landau S, Filbey F, Gruzelier JH, Sham PC, Frangou S, Murray RM. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. Neuroimage. 2005;27(4):960-8.
147. Roth WT, Cannon EH. Some features of the auditory evoked response in schizophrenics. Arch Gen Psychiatry. 1972;27(4):466-71.
148. Turetsky BI, Colbath EA, Gur RE. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol Psychiatry. 1998;43(2):84-96.
149. Braff DL. Information processing and attention dysfunctions in schizophrenia. Schizophr Bull. 1993;19(2):233-59.
150. Duncan CC. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr Bull. 1988;14(2):199-203.
151. Polich J, Corey-Bloom J. Alzheimer'S disease and P300: review and evaluation of task and modality. Curr Alzheimer Res. 2005;2(5):515-25.
152. O'Donnell BF, Vohs JL, Hetrick WP, Carroll CA, Shekhar A. Auditory eventrelated potential abnormalities in bipolar disorder and schizophrenia. Int J Psychophysiol. 2004;53(1):45-55.
153. Polich J, Pollock VE, Bloom FE. Meta-analysis of P300 amplitude from males at risk for alcoholism. Psychol Bull. 1994;115(1):55-73.
154. Singh SM, Basu D. The P300 event-related potential and its possible role as an endophenotype for studying substance use disorders: a review. Addict Biol. 2009;14(3):298-309.
155. Ilan AB, Gevins A, Coleman M, ElSohly MA, de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol. 2005;16(5-6):487-96.
156. Roser P, Juckel G, Rentzsch J, Nadulski T, Gallinat J, Stadelmann AM. Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. Eur Neuropsychopharmacol. 2008;18(8):569-77.
157. Johnson JP, Muhleman D, MacMurray J, Gade R, Verde R, Ask M, Kelley J, Comings DE. Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry. 1997;2(2):169-71.
158. Solowij N, Michie PT, Fox AM. Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav. 1991;40(3):683-8.
159. Solowij N, Michie PT, Fox AM. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry. 1995;37(10):731-9.
160. Kempel P, Lampe K, Parnefjord R, Hennig J, Kunert HJ. Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology. 2003;48(2):95-101.
161. Skosnik PD, Park S, Dobbs L, Gardner WL. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry Res. 2008;157(1- 3):279-82.
162. Patrick G, Straumanis JJ, Struve FA, Nixon F, Fitz-Gerald MJ, Manno JE, Soucair M. Auditory and visual P300 event related potentials are not altered in medically and psychiatrically normal chronic marihuana users. Life Sci. 1995;56(23-24):2135-40.
163. de Sola S, Tarancon T, Pena-Casanova J, Espadaler JM, Langohr K, Poudevida S, Farré M, Verdejo-García A, de la Torre R. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study. Psychopharmacology (Berl). 2008;200(3):425-37.
164. Naatanen R, Alho K. Generators of electrical and magnetic mismatch responses in humans. Brain Topogr. 1995;7(4):315-20.
165. Rinne T, Alho K, Ilmoniemi RJ, Virtanen J, Naatanen R. Separate time behaviors of the temporal and frontal mismatch negativity sources. Neuroimage. 2000;12(1):14-9.
166. Naatanen R, Kahkonen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol. 2009;12(1):125-35.
167. Umbricht D, Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res. 2005;76(1):1-23.
168. Umbricht D, Koller R, Schmid L, Skrabo A, Grubel C, Huber T, Stassen H. How specific are deficits in mismatch negativity generation to schizophrenia? Biol Psychiatry. 2003;53(12):1120-31.
169. Juckel G, Roser P, Nadulski T, Stadelmann AM, Gallinat J. Acute effects of Delta9- tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr Res. 2007;97(1-3):109-17.
170. Roser P, Della B, Norra C, Uhl I, Brune M, Juckel G. Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur Arch Psychiatry Clin Neurosci. In press 2010.
171. Hillyard SA, Hink RF, Schwent VL, Picton TW. Electrical signs of selective attention in the human brain. Science. 1973;182(108):177-80.
172. Naatanen R, Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology. 1987;24(4):375-425.
173. Rosburg T, Boutros NN, Ford JM. Reduced auditory evoked potential component N100 in schizophrenia--a critical review. Psychiatry Res. 2008;161(3):259-74.
174. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff DL, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008;64(12):1051-9.
175. Skosnik PD, Krishnan GP, Vohs JL, O'Donnell BF. The effect of cannabis use and gender on the visual steady state evoked potential. Clin Neurophysiol. 2006;117(1):144-56.
176. Skosnik PD, Edwards CR, O'Donnell BF, Steffen A, Steinmetz JE, Hetrick WP. Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology. 2008;33(6):1432-40.
177. Edwards CR, Skosnik PD, Steinmetz AB, Vollmer JM, O'Donnell BF, Hetrick WP. Assessment of forebrain-dependent trace eyeblink conditioning in chronic cannabis users. Neurosci Lett. 2008;439(3):264-8.
178. Barkus E, Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med. 2008;38(9):1267-76.
179. Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, Lewis S. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology. 2008;41(6):371-8.
180. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med. 2003;33(1):23-32.
181. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabisassociated psychosis. Schizophr Res. 1995;15(3):277-81.
182. Miller P, Lawrie SM, Hodges A, Clafferty R, Cosway R, Johnstone EC. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2001;36(7): 338-42.
183. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007;151(1-2):151-4.
184. Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008;65(11):1269-74.
185. Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res. 2008,106(2-3):286-93.
186. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacolog y. 2006;31(12):2748-57.
187. Schiffman J, Nakamura B, Earleywine M, LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Res. 2005;134(1):37-42.
188. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Geneenvironment interplay between cannabis and psychosis. Schizophr Bull. 2008;34(6):1111-21.
189. Williams JH, Wellman NA, Rawlins JN. Cannabis use correlates with schizotypy in healthy people. Addiction. 1996;91(6):869-77.
190. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res. 2001;48(1):83-92.
191. Dumas P, Saoud M, Bouafia S, Gutknecht C, Ecochard R, Dalery J, Rochet T, d'Amato T. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res. 2002;109(1):27-35.
192. Earleywine M. Schizotypy, marijuana, and differential item functioning. Hum Psychopharmacol. 2006;21(7):455-61.
193. Veling W, Mackenbach JP, van Os J, Hoek HW. Cannabis use and genetic predisposition for schizophrenia: a case-control study. Psychol Med. 2008;38(9):1251-6.
194. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-Omethyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005;57(10):1117-27.
195. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC, Owen MJ. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 2007;191:402-7.
196. Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull. 2008;34(1):9-12.
197. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl). 2007;192(3):325-36.
198. Chakrabarti B, Kent L, Suckling J, Bullmore E, Baron-Cohen S. Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces. Eur J Neurosci. 2006;23(7):1944-8.
199. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, MacMurray J. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry. 1997;2(2):161-8.
200. Schmidt LG, Samochowiec J, Finckh U, Fiszer-Piosik E, Horodnicki J, Wendel B, Rommelspacher H, Hoehe MR Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002;65(3):221-4.
201. Zhang PW, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR. Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatr y. 2004;9(10):916-31.
202. Ponce G, Hoenicka J, Rubio G, Ampuero I, Jimenez-Arriero MA, Rodriguez-Jimenez R, Palomo T, Ramos JA. Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/ hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry. 2003;8(5):466-7.
203. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry. 2002;7(5):515-8.
204. Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez- Arriero MA, Perez-Hernandez E, Ampuero I, Ramos-Atance JA, Palomo T, Rubio G. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci. 2006;256(7):437-41.
205. Chavarria-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori A, Contreras S, Medina R, Ramírez M, Salazar R, Raventos H, Escamilla MA. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;147(3):279-84.
206. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet. 2000;10(3):149-51.
207. Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet. 2001;105(8):749-52.
208. Seifert J, Ossege S, Emrich HM, Schneider U, Stuhrmann M. No association of CNR1 gene variations with susceptibility to schizophrenia. Neurosci Lett. 2007;426(1):29-33.
209. Hamdani N, Tabeze JP, Ramoz N, Ades J, Hamon M, Sarfati Y, Boni C, Gorwood P. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol. 2008;18(1):34-40.
210. Allebeck P, Adamsson C, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scand. 1993;88(1):21-4. Erratum in: Acta Psychiatr Scand. 1993;88(4):304.
211. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-9.
212. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996;40(11):1155-63.
213. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34(3):468-75.
214. Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66(2-3):125-35.
215. Addington J, Addington D. Effect of substance misuse in early psychosis. Br J Psychiatry Suppl. 1998;172(33):134-6.
216. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):69-72.
217. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown GM, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J Clin Psychiatry. 1991;52(1):26-30.
218. Andreasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand. 1989;79(5):505-10.
219. Allebeck P, Adamsson C, Engstrom A, Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr Scand. 1993;88(1):21-4.
220. McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S, Murray RM. Cannabis and acute psychosis. Schizophr Res. 1994;13(2):161-7.
221. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004;161(3):501-6.
222. Macleod J. Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al. Psychol Med. 2007;37(7):913-6.
223. Collip D, Myin-Germeys I, Van Os J. Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull. 2008;34(2):220-5.
224. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry. 2009;21(2):152-62.
225. D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/ schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259(7):413-31.
226. Hall W, Pacula R. Cannabis use and dependence: public health and public policy. London: Cambridge University Press; 2003.